Real‐world experience with eculizumab and switching to ravulizumab for generalized myasthenia gravis
Sign Up to like & getrecommendations! Published in 2024 at "Annals of Clinical and Translational Neurology"
DOI: 10.1002/acn3.52051
Abstract: Eculizumab and ravulizumab are complement protein C5 inhibitors, showing efficacy and tolerability for patients with anti‐acetylcholine receptor‐positive (AChR+) generalized myasthenia gravis (gMG) in phase 3 clinical trials and subsequent analyses. The purpose of the present… read more here.
Keywords: eculizumab switching; generalized myasthenia; switching ravulizumab; real world ... See more keywords
Eculizumab is Associated With Increased Infection Rates and Infection Related Mortality in Children With Thrombotic Microangiopathy After HCT
Sign Up to like & getrecommendations! Published in 2025 at "American Journal of Hematology"
DOI: 10.1002/ajh.70022
Abstract: Complement C5 inhibition can be used to treat hematopoietic cell transplant‐associated thrombotic microangiopathy (TA‐TMA) but may impact infectious organism clearance, impeding opsonization and lysis. The infectious risks of eculizumab exposure after hematopoietic cell transplant (HCT)… read more here.
Keywords: infection rates; mortality; hct; eculizumab ... See more keywords
Nationwide study of paroxysmal nocturnal hemoglobinuria in South Korea: paradox of eculizumab
Sign Up to like & getrecommendations! Published in 2020 at "Annals of Hematology"
DOI: 10.1007/s00277-020-04133-z
Abstract: Eculizumab is effective in managing patients with paroxysmal nocturnal hemoglobinuria (PNH). In South Korea, the financial support for eculizumab therapy is extended by the National Health Insurance Services (NHIS) only to patients with high-risk PNH… read more here.
Keywords: group; paroxysmal nocturnal; eculizumab; nocturnal hemoglobinuria ... See more keywords
United States clinical practice experience with eculizumab in myasthenia gravis: symptoms, function, and immunosuppressant therapy use
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Neurology"
DOI: 10.1007/s00415-024-12569-w
Abstract: The phase 3 REGAIN study and its open-label extension demonstrated the efficacy of the complement C5 inhibitor eculizumab in patients with treatment-refractory, acetylcholine receptor antibody–positive generalized myasthenia gravis (gMG). The aim of the ELEVATE study… read more here.
Keywords: united states; treatment; myasthenia gravis; clinical practice ... See more keywords
A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patients
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Neurology"
DOI: 10.1007/s00415-024-12588-7
Abstract: Eculizumab, a complement active antibody, and efgartigimod, an Fc fragment that blocks neonatal Fc receptor, are both approved to treat generalized myasthenia gravis (gMG) patients. The objective of this study is to describe the clinical… read more here.
Keywords: efgartigimod; eculizumab efgartigimod; myasthenia gravis; eculizumab ... See more keywords
Results from multinational phase 3 studies of ravulizumab (ALXN1210) versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria: subgroup analysis of Japanese patients
Sign Up to like & getrecommendations! Published in 2020 at "International Journal of Hematology"
DOI: 10.1007/s12185-020-02934-6
Abstract: Ravulizumab demonstrated noninferior efficacy and comparable safety to eculizumab in two open-label, phase 3 studies in patients with paroxysmal nocturnal hemoglobinuria (PNH) who complement inhibitor-naive (Study 301) or were previously treated with eculizumab (Study 302).… read more here.
Keywords: ravulizumab; study; japanese patients; eculizumab ... See more keywords
Comment on “Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab”
Sign Up to like & getrecommendations! Published in 2020 at "Clinical Pharmacokinetics"
DOI: 10.1007/s40262-020-00950-7
Abstract: After reading the review article by Wijnsma et al. [1] with great interest, we would like to comment on the utility of eculizumab dose monitoring in pregnancy. While Wijnsma et al. describe a strategy for… read more here.
Keywords: comment; comment pharmacology; pharmacology; eculizumab ... See more keywords
Eculizumab: A Review in Generalized Myasthenia Gravis
Sign Up to like & getrecommendations! Published in 2018 at "Drugs"
DOI: 10.1007/s40265-018-0875-9
Abstract: The humanized monoclonal antibody eculizumab (Soliris®) is a complement inhibitor indicated for use in anti-acetylcholine receptor (AChR) antibody-positive adults with generalized myasthenia gravis (gMG) in the USA, refractory gMG in the EU, or gMG with… read more here.
Keywords: eculizumab review; generalized myasthenia; eculizumab; myasthenia gravis ... See more keywords
Atypical hemolytic uremic syndrome due to DGKE mutation and response to eculizumab: lessons for the clinical nephrologist
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Nephrology"
DOI: 10.1007/s40620-020-00925-8
Abstract: An 18-month-old white boy presented with non-bloody diarrhea and pallor and one week of cough and nasal congestion. On examination, he was hypertensive (115/99) and tachycardic (140 bpm). Pertinent labs included normocytic hemolytic anemia with… read more here.
Keywords: atypical hemolytic; uremic syndrome; hemolytic uremic; eculizumab ... See more keywords
Hemolytic Uremic Syndrome
Sign Up to like & getrecommendations! Published in 2020 at "Current Treatment Options in Pediatrics"
DOI: 10.1007/s40746-020-00216-1
Abstract: The emergence of specific treatment of atypical hemolytic uremic syndrome (aHUS) using eculizumab has allowed renal function recovery and safe kidney transplantation (KT). Early and precise recognition of complement-mediated (CM) atypical HUS (aHUS) is challenging… read more here.
Keywords: hus; uremic syndrome; treatment; hemolytic uremic ... See more keywords
Successful 7-Year Eculizumab Treatment of Plasmapheresis-Resistant Recurrent Atypical Hemolytic-Uremic Syndrome due to Complement Factor H Hybrid Gene: A Case Report.
Sign Up to like & getrecommendations! Published in 2018 at "Transplantation proceedings"
DOI: 10.1016/j.transproceed.2018.02.012
Abstract: Atypical hemolytic-uremic syndrome (aHUS) is an extremely rare disease, and up to 70% of the patients have a genetic mutation in the encoding components of complement activation or anti-complement factor H autoantibodies. The risk of… read more here.
Keywords: eculizumab; eculizumab treatment; hybrid gene; complement factor ... See more keywords